Macugen for Histoplasmosis

Exclusion Criteria

• •Features of any condition other than OHS such as AMD, or pathologic or myopic angioid streaks associated with CNV in the study eye,
• •Area of CNV that is less than 50% of the total lesion not including area of prior laser treatment, previous rip of retinal pigment epithelium,
• •Vitelliform-like lesion,
• •Telangiectasia,
• •Central serous retinopathy,
• •Serous pigment epithelial detachment without CNV,
• •Any significant ocular disease other than CNV that could compromise vision in the study eye, such as amblyopia, glaucoma, optic neuropathy, or diabetic retinopathy,
• •Inability to obtain photographs to document CNV,
• •Presence of atrophy/scar in the center of fovea,
• •Presence of vitreo-retinal traction over the center of the fovea,
• •History of treatment for CNV in the study eye other than non-foveal laser photocoagulation,within 12 weeks prior to enrollment
• •Participation in another clinical trial or use of another investigational new drug within 12 weeks of the full extent of the study treatment,
• •Intraocular surgery within the last two months,
• •Capsulectomy within the last month in the study eye